NEW YORK ─ Telehealth firm Ro on Wednesday announced the acquisition of at-home diagnostic testing company Kit for an undisclosed amount.
New York-based Ro said the acquisition expands the lab infrastructure associated with its primary care platform and builds on its telehealth, pharmacy, lab processing, and in-home testing and care services.
Kit sells physician-ordered diagnostic tests, including finger-prick blood assays, blood pressure tests, and weight measurement tools that are shipped to patients. The tests are self-administered by the patient and providers are notified as soon as results are ready. The firm processes its tests at a high-complexity, CLIA-certified and CAP-accredited lab in San Francisco.
Ro said it will integrate Kit's diagnostic infrastructure with its existing in-home capabilities, including Workpath — an on-demand, in-home care and diagnostic services application programming interface, or API.
"Combining Kit with Workpath, our existing in-home care API, will enable Ro and other healthcare companies to send either a healthcare professional or test kit to a patient's home with the click of a button," Zachariah Reitano, cofounder and CEO of Ro, said in a statement.
Ro said its affiliated providers will be able to order Kit's diagnostic tests for patients directly through Ro's platform, providing diagnostic and health data for conditions such as sexual health, fertility, cholesterol, hypertension, and diabetes.